» Articles » PMID: 36457842

Distribution and Frequency of Common Mutations in Gene of Detected by Xpert MTB/RIF and Identification of Residential Areas of Rifampicin Resistant-TB Cases: A First Retrospective Study from Mizoram, Northeast India

Abstract

Background: Rifampicin resistance (RR) is a surrogate marker of multidrug-resistant tuberculosis. The aim of this study is to determine the frequency of the commonly mutated probes for gene and locate the residential areas of the Rifampicin Resistant-TB (RR-TB) patients in a high endemic zone of Northeast India.

Methods: Archived data of 13,454 Xpert MTB/RIF reports were evaluated retrospectively between 2014 and 2021. Socio-demographic and available clinical information were reviewed and analyzed for RR-TB cases only. Logistic Regression was used to analyze the parameters with respect to probe types. P-value ≤ 0.05 was considered to be statistically significant.

Results: 2,894 patients had infection out of which 460 were RR-TB, which was most prevalent among 25-34 years. The most common mutation occurred in probe A (25.9 %) followed by E (23.5 %), D (9.8 %), B (2.6 %) and the least in C (0.2 %). High prevalence (34.3 %) of probe mutation combinations were also found: probes AB (0.4 %), AD (32.8 %), AE (0.4 %), DE (0.2 %) and ADE (0.4 %). Seventeen patients (3.7 %) were found without any missing probes. RR-TB patients were mostly located in Aizawl North -III, South -II and East -II constituencies.

Conclusion: This study provides genetic pattern of drug resistance accountable for RR over the past years in Mizoram which will help local clinicians in the initiation of correct treatment. Also, our findings provide a baseline data on the magnitude of RR-TB within the state and identification of the residential areas can help local health authorities in planning surveillance programs to control the spread of RR-TB.

Citing Articles

Efficacy of Xpert MTB/RIF assay in detecting Mycobacterium tuberculosis in samples with different results by smear and culture in a coastal city with high incidence of tuberculosis.

Feng G, Jiang H, Chen Y BMC Infect Dis. 2025; 25(1):55.

PMID: 39799307 PMC: 11725220. DOI: 10.1186/s12879-025-10446-z.


The pattern of rpoB gene mutation of Mycobacterium tuberculosis and predictors of rifampicin resistance detected by GeneXpert MTB/RIF assay in Tanzania.

Torokaa P, Majigo M, Kileo H, Urio L, Mbwana M, Monah M PLoS One. 2024; 19(8):e0296563.

PMID: 39186753 PMC: 11346956. DOI: 10.1371/journal.pone.0296563.


Factors influencing false-positive results of rifampicin resistance detected by Xpert MTB/RIF: A retrospective study in Zhejiang, China.

Wu G, Wang J, Xu X, Wei H, Cai L, Liu L Heliyon. 2024; 10(11):e31680.

PMID: 38841482 PMC: 11152942. DOI: 10.1016/j.heliyon.2024.e31680.

References
1.
Nguessan Kouassi K, Riccardo A, Dutoziet Christian C, Andre G, Ferilaha C, Hortense S . Genotyping of mutations detected with GeneXpert. Int J Mycobacteriol. 2016; 5(2):142-7. DOI: 10.1016/j.ijmyco.2016.01.001. View

2.
Alemu A, Tadesse M, Seid G, Mollalign H, Eshetu K, Sinshaw W . Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia. BMC Infect Dis. 2020; 20(1):87. PMC: 6993378. DOI: 10.1186/s12879-020-4817-2. View

3.
Mani C, Selvakumar N, Narayanan S, Narayanan P . Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J Clin Microbiol. 2001; 39(8):2987-90. PMC: 88277. DOI: 10.1128/JCM.39.8.2987-2990.2001. View

4.
Ochang E, Udoh U, Emanghe U, Tiku G, Offor J, Odo M . Evaluation of rifampicin resistance and 81-bp rifampicin resistant determinant region of rpoB gene mutations of Mycobacterium tuberculosis detected with XpertMTB/Rif in Cross River State, Nigeria. Int J Mycobacteriol. 2017; 5 Suppl 1:S145-S146. DOI: 10.1016/j.ijmyco.2016.09.007. View

5.
Khaja Mafij Uddin M, Rahman A, Ather M, Ahmed T, Rahman S, Ahmed S . Distribution and Frequency of B Mutations Detected by Xpert MTB/RIF Assay Among Beijing and Non-Beijing Rifampicin Resistant Isolates in Bangladesh. Infect Drug Resist. 2020; 13:789-797. PMC: 7073589. DOI: 10.2147/IDR.S240408. View